HICON - sodium iodide I 131 solution
Jubilant DraxImage Inc.

HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use HICON® safely and effectively. See full prescribing information for HICON®.
HICON® (for the preparation of sodium iodide I 131 solution or sodium iodide I 131 capsules), therapeutic, for oral use.
Initial U.S. Approval: 1971

INDICATIONS AND USAGE
HICON® is a radioactive therapeutic agent indicated for the treatment of hyperthyroidism and selected cases of carcinoma of the thyroid. (1)

DOSAGE AND ADMINISTRATION
• The concentrated sodium iodide I 131 solution USP provided with HICON® must be diluted. (2.2)
• See Full Prescribing Information for important administration instructions and dilution and preparation instructions for sodium iodide I 131 tablets or oral solution. (2.2, 2.4)
• The recommended dose is based on the thyroid gland uptake as well as the size of the gland:
  • Treatment of Hyperthyroidism: Recommended dosage is 148 to 370 megabecquerels (MBq) [4 to 10 millicuries (mCi)]. (2.3)
  • Treatment of Thyroid Carcinoma: Recommended dosage is 1,110 to 33,700 MBq (30 to 100 mCi). (2.3)

DOSAGE FORMS AND STRENGTHS
Vials: Sodium Iodide I 131 Solution (9,250 MBq, 18,500 MBq, and 37,000 MBq at time of calibration) for the preparation of sodium iodide I 131 capsules, therapeutic or sodium iodide I 131 solution, therapeutic. (3)

CONTRAINDICATIONS
Patients with vomiting and diarrhea. (4)
Pregnancy. (4)
Lactation. (4)
Patients receiving concurrent anti-thyroid therapy.

WARNINGS AND PRECAUTIONS
• Radiation-induced thyroiditis may cause or worsen hyperthyroidism. Consider pre-treatment with anti-thyroid medications. (5.1)
• Multiple non-thyroid radiation toxicities, including hematopoietic suppression: Individualize dose and monitor for toxicity. (5.2)
• Fetal toxicity: May cause severe and irreversible hypothyroidism in the neonate. Verify absence of pregnancy before administering the product. (5.4, 8.1, 8.3)
• Radiation exposure to breast tissue with lactation: Sodium iodide I 131 concentrates in the breast of lactating women. Discontinue lactation 6 weeks prior to therapy. (5.5, 8.2)

ADVERSE REACTIONS
Common adverse reactions reported with therapeutic doses of sodium iodide I 131 include local swelling, radiation sickness, salivary gland dysfunction, bone marrow depression, lacrimal gland dysfunction, hypothyroidism, hyperthyroidism, thyrotoxic crisis, acute leukemia, solid cancer. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Jubilant DraxImage Inc. at 1-888-633-5343 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS
Many drugs and iodine-containing foods interfere with the accumulation of radioiodide by the thyroid. Instruct patients to maintain a low-iodide diet (2 weeks) and discontinue anti-thyroid therapy (3 days) before administration. (5.8, 7)

USE IN SPECIFIC POPULATIONS
• Females and Males of Reproductive Potential: May impair fertility in females and males. (5.6, 8.3)
• Geriatric Use: Dose selection may be necessary for geriatric patients due to possible decreased renal function. (8.5)
• Renal Impairment: May increase radiation exposure. (5.2, 8.6)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 8/2016
FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE
HICON® is indicated for the treatment of hyperthyroidism and selected cases of thyroid carcinoma.
2 DOSAGE AND ADMINISTRATION

2.1 Radiation Safety
- HICON® is a radioactive drug. Handle with appropriate safety measures to minimize radiation exposure to the patient and healthcare workers [see Warnings and Precautions (5.7)]:
  - Use only by, or under the direction of, physicians who are qualified by specific training and experience in the safe use and handling of radioactive materials, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radiopharmaceuticals.
  - Use waterproof gloves when handling and administering the product.
  - Maintain adequate shielding during the life of the product.
  - Measure patient dose with a suitable radioactivity calibration system immediately prior to administration.

2.2 Important Administration Instructions
- Do not directly administer the concentrated sodium iodide I 131 solution provided with HICON® to patients. The concentrated sodium iodide I 131 solution must be diluted and prepared prior to administration [see Dosage and Administration (2.4)].
- Obtain a pregnancy test in females of reproductive potential prior to administration to verify the absence of pregnancy [see Contraindications (4) and Use in Specific Populations (8.1,8.3)].
- Instruct patients to fast at least 2 hours before and 2 hours after administration to ensure absorption.
- Instruct patients to hydrate before and after administration of sodium iodide I 131 and to void frequently to enhance urinary elimination of the radioiodide that is not absorbed by the thyroid gland [see Warnings and Precautions (5.2)].
- Instruct patients to maintain a low-iodide diet two weeks prior to radioiodide administration and continue for several days during the uptake or imaging process [see Warnings and Precautions (5.8) and Drug Interactions (7)].
- Instruct patients to discontinue the anti-thyroid therapy three days before administration of sodium iodide I 131 [see Warnings and Precautions (5.8) and Drug Interactions (7)].
- For patients with a history of renal impairment, evaluate renal function for therapeutic planning and consider dosimetry [see Use in Specific Populations (8.6)].
- Obtain a complete blood count within one month of therapy. If patients show leukopenia or thrombocytopenia, dosimetry should be used to determine a safe sodium iodide I 131 activity, while delivering less than 2 Gy to the bone marrow [see Warnings and Precautions (5.2)].

2.3 Recommended Dosage and Administration

Individualization of Therapy
The recommended dose for orally administered sodium iodide I 131 capsules or solution is based on the thyroid gland uptake as well as the size of the gland. Thyroidal uptake and size should be determined by the physician prior to treatment and may be useful in calculating the therapeutic dose to be administered to the individual patient.

Treatment of Hyperthyroidism
The recommended dose is 148 to 370 MBq (4 to 10 mCi) administered orally. Toxic nodular goiter may require a larger dose.

Treatment of Thyroid Carcinoma
The recommended dose is 1100 to 3700 MBq (30 to 100 mCi) administered orally. For subsequent ablation of metastases, the recommended dose is 3700 to 7400 MBq (100 to 200 mCi) administered orally.

2.4 Dilution and Preparation Instructions
Preparation of Dilute Sodium Iodide I 131 Solution USP

1. Using the calibration date and radionuclidic concentration on the label of the product vial, calculate the required volume to produce the necessary dose in MBq or mCi.
2. Using a shielded syringe, remove the required volume.
3. Using the shielded syringe, transfer the required volume to a suitably shielded receiving vial.
4. Add diluent solution to the receiving vial to produce a final dose of the desired volume.
5. The recommended diluent is Purified Water containing 0.2 % sodium thiosulfate as a reducing agent. Acidic diluents should not be used as they may cause the pH to drop below 7.5 and stimulate the volatilization of Iodine I-131 hydriodic acid.
6. Present the dose in a shielded container for administration to the patient with a straw.

Preparation of Sodium Iodide I 131 Capsules USP

1. HICON® includes one large gelatin capsule and one small gelatin capsule for each dose prepared. Each large capsule is empty and each small capsule contains approximately 300 mg of dibasic sodium phosphate anhydrous as the absorbing buffer.
2. Using the calibration date and radionuclidic concentration on the label of the product vial, calculate the required volume to produce the necessary dose in MBq or mCi.
3. Open one large capsule supplied with HICON® by pulling apart the capsule into two pieces as illustrated below:

![Illustration of opening a large capsule](image1)

4. Insert an unopened small capsule supplied with HICON® into the bottom half of the empty large capsule as illustrated below:

![Illustration of inserting a small capsule](image2)

5. With an appropriate syringe, withdraw the required volume of sodium iodide I 131 Solution USP (maximum 150 microliters) from the vial as illustrated below:
6. Inject into the center of the small capsule through the top as illustrated below:

7. Slip the upper half of the large capsule over the bottom half to completely cover the small capsule and push down gently until locked as illustrated below:

8. Measure the patient dose in a suitable radioactivity calibration system immediately prior to administration.

9. Prepared capsules may be stored in a suitable polypropylene container and placed inside a lead pot until use, within seven days.

2.5 Radiation Dosimetry

- The biokinetic modeling and radiation dose distributions associated with thyroid uptake of iodide I 131 depend on dietary intake of stable iodide and assume normal production of thyroid hormone. Table 1 shows a range of uptake percentages in an average adult (73.7 kg reference model). Table 1 is not intended to be used for treatment planning.

- For a thyroid blocked from iodide uptake in the production of hormones, the effective half-life of iodide I 131 is approximately 1.4 hours; for "low" to "high" uptake, the effective half-life of I 131 ranges from approximately 80 to 90 hours.

**Table 1**

<p>| Absorbed dose per unit activity sodium iodide I 131 administered orally (mGy/MBq) in adult (73.7-kg reference model) |</p>
<table>
<thead>
<tr>
<th>Organ</th>
<th>Blocked thyroid (0% $A_0$)</th>
<th>Low uptake† (16% $A_0$)</th>
<th>Medium uptake† (26% $A_0$)</th>
<th>High uptake† (36% $A_0$)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adrenals</td>
<td>0.044</td>
<td>0.051</td>
<td>0.055</td>
<td>0.059</td>
</tr>
<tr>
<td>Bone surfaces</td>
<td>0.030</td>
<td>0.089</td>
<td>0.12</td>
<td>0.16</td>
</tr>
<tr>
<td>Brain</td>
<td>0.021</td>
<td>0.093</td>
<td>0.13</td>
<td>0.17</td>
</tr>
<tr>
<td>Breast</td>
<td>0.020</td>
<td>0.038</td>
<td>0.048</td>
<td>0.058</td>
</tr>
<tr>
<td>Gallbladder wall</td>
<td>0.037</td>
<td>0.043</td>
<td>0.046</td>
<td>0.049</td>
</tr>
<tr>
<td>Gastrointestinal tract</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Esophagus</td>
<td>0.024</td>
<td>0.10</td>
<td>0.14</td>
<td>0.19</td>
</tr>
<tr>
<td>Stomach wall</td>
<td>0.87</td>
<td>0.77</td>
<td>0.71</td>
<td>0.66</td>
</tr>
<tr>
<td>Small intestine wall</td>
<td>0.035</td>
<td>0.033</td>
<td>0.032</td>
<td>0.032</td>
</tr>
<tr>
<td>Colon wall</td>
<td>0.14</td>
<td>0.14</td>
<td>0.14</td>
<td>0.14</td>
</tr>
<tr>
<td>(Upper large intestine wall)</td>
<td>0.12</td>
<td>0.12</td>
<td>0.12</td>
<td>0.12</td>
</tr>
<tr>
<td>(Lower large intestine wall)</td>
<td>0.17</td>
<td>0.17</td>
<td>0.17</td>
<td>0.16</td>
</tr>
<tr>
<td>Heart wall</td>
<td>0.062</td>
<td>0.089</td>
<td>0.10</td>
<td>0.12</td>
</tr>
<tr>
<td>Kidneys</td>
<td>0.27</td>
<td>0.27</td>
<td>0.27</td>
<td>0.27</td>
</tr>
<tr>
<td>Liver</td>
<td>0.050</td>
<td>0.093</td>
<td>0.12</td>
<td>0.14</td>
</tr>
<tr>
<td>Lungs</td>
<td>0.053</td>
<td>0.10</td>
<td>0.13</td>
<td>0.15</td>
</tr>
<tr>
<td>Muscles</td>
<td>0.026</td>
<td>0.084</td>
<td>0.12</td>
<td>0.15</td>
</tr>
<tr>
<td>Ovaries</td>
<td>0.038</td>
<td>0.037</td>
<td>0.036</td>
<td>0.035</td>
</tr>
<tr>
<td>Pancreas</td>
<td>0.060</td>
<td>0.064</td>
<td>0.066</td>
<td>0.068</td>
</tr>
<tr>
<td>Red marrow</td>
<td>0.031</td>
<td>0.072</td>
<td>0.095</td>
<td>0.12</td>
</tr>
<tr>
<td>Salivary glands</td>
<td>0.27</td>
<td>0.22</td>
<td>0.19</td>
<td>0.16</td>
</tr>
<tr>
<td>Skin</td>
<td>0.019</td>
<td>0.043</td>
<td>0.057</td>
<td>0.071</td>
</tr>
<tr>
<td>Spleen</td>
<td>0.064</td>
<td>0.069</td>
<td>0.072</td>
<td>0.075</td>
</tr>
<tr>
<td>Testes</td>
<td>0.025</td>
<td>0.024</td>
<td>0.023</td>
<td>0.22</td>
</tr>
<tr>
<td>Thymus</td>
<td>0.024</td>
<td>0.10</td>
<td>0.14</td>
<td>0.19</td>
</tr>
<tr>
<td>Thyroid</td>
<td>2.2</td>
<td>280†</td>
<td>430†</td>
<td>580†</td>
</tr>
<tr>
<td>Urinary bladder wall</td>
<td>0.54</td>
<td>0.45</td>
<td>0.39</td>
<td>0.34</td>
</tr>
<tr>
<td>Uterus</td>
<td>0.045</td>
<td>0.042</td>
<td>0.040</td>
<td>0.038</td>
</tr>
<tr>
<td>Remaining organs</td>
<td>0.029</td>
<td>0.084</td>
<td>0.11</td>
<td>0.15</td>
</tr>
<tr>
<td><strong>Effective dose per administered activity (mSv/MBq)</strong></td>
<td><strong>0.28</strong></td>
<td><strong>14†</strong></td>
<td><strong>22†</strong></td>
<td><strong>29†</strong></td>
</tr>
</tbody>
</table>

* Table 1 is not intended for treatment planning.
† These columns are not applicable to estimate organ or effective doses in patients following thyroidectomy. In patients with thyroid cancer following thyroidectomy, organ and effective doses can be estimated from the "blocked"-thyroid-uptake values.
‡ These values presume unimpeded production of thyroid hormone and may not be applicable to estimate thyroid dose and effective dose in patients who have had previous treatment with I 131 for hyperthyroidism.
3 DOSAGE FORMS AND STRENGTHS

HICON® is available in 1 mL size, clear vials containing a colorless, aqueous, concentrated Sodium Iodide I 131 Solution [9,250 MBq, 18,500 MBq, and 37,000 MBq at time of calibration] for the preparation of sodium iodide I 131 capsules, therapeutic or sodium iodide I 131 solution, therapeutic. Refer to Table 2 for the radioactivity and volume in each vial. Large gelatin capsules (empty) and small gelatin capsules containing approximately 300 mg of dibasic sodium phosphate anhydrous as the absorbing buffer are supplied along with HICON® for the preparation of sodium iodide I 131 capsules, therapeutic.

Table 2 HICON® Concentrated Sodium Iodide I 131 Solution

<table>
<thead>
<tr>
<th>Total Radioactivity/Vial MBq</th>
<th>Solution Volume (mL)/Vial</th>
</tr>
</thead>
<tbody>
<tr>
<td>9,250 (250 mCi)</td>
<td>0.25</td>
</tr>
<tr>
<td>18,500 (500 mCi)</td>
<td>0.5</td>
</tr>
<tr>
<td>37,000 (1000 mCi)</td>
<td>1</td>
</tr>
</tbody>
</table>

*At time of calibration.

4 CONTRAINDICATIONS

HICON® is contraindicated in:
- Patients with vomiting and diarrhea [see Warning and Precautions (5.7)].
- Pregnancy [see Warnings and Precautions (5.4), see Use in Specific Populations (8.1)].
- Lactation [see Warnings and Precautions (5.5)].
- Patients receiving concurrent anti-thyroid therapy [see Warning and Precautions (5.1) and Drug Interactions (7)].

5 WARNINGS AND PRECAUTIONS

5.1 Radiation-induced Thyroiditis

Sodium iodide I 131 may cause thyroiditis with release of thyroid hormone, which may aggravate hyperthyroidism and thyrotoxic cardiac disease [see Adverse Reactions (6)]. When treating hyperthyroidism, consider pre-treatment anti-thyroid medication to help deplete the thyroid hormone. Discontinue the anti-thyroid therapy three days before administration of sodium iodide I 131 [see Drug Interactions (7)]. Consider a beta-blocker pre or post-treatment to minimize the risk of hyperthyroidism and thyroid storm.

The thyroiditis may cause gland enlargement resulting in tenderness and swelling of the neck, pain on swallowing, sore throat, and cough; which may occur approximately the third day after sodium iodide I 131 administration. Consider management with pain-reliever or anti-inflammatory medications.

5.2 Radiation-induced Toxicities

Sodium Iodide I 131 may cause radiation induced toxicities [see Adverse Reactions (6)]:
- Dose-dependent fatalities (bone marrow suppression, malignancy).
- Dose-dependent hematopoietic suppression which manifests as a transient thrombocytopenia or neutropenia 3-5 weeks following sodium iodide I 131 administrations, may lead to increased susceptibility to infections or bleeding.
- Salivary gland toxicity: sialadenitis, xerostomia.
- Lacrimal gland toxicity: conjunctivitis, xerophthalmia, and epiphora.
Obtain a complete blood count within one month of therapy. If patients show leukopenia or thrombocytopenia, dosimetry should be used to determine a safe sodium iodide I 131 activity, while delivering less than 2 Gy to the bone marrow.

Advise good hydration for one week following sodium iodide I 131 administration and stimulate salivary flow via a sialagogue (e.g. sugar-free candy or gum, pilocarpine, and ascorbic acid) to reduce radiation exposure to the salivary glands.

Advise patients to void frequently after administration of radioiodide to enhance excretion.

5.3 Hypersensitivity Reactions
Hypersensitivity reactions including anaphylaxis may occur in patients who receive sodium iodide I 131. Although iodide is not considered an allergen, hypersensitivity reactions may occur in relation with excipients or chemical component of the capsule, such as sodium thiosulfate. Obtain and document an allergy history, particularly a sulfite allergy. Emergency resuscitation equipment and personnel should be immediately available [see Adverse Reactions (6)].

5.4 Fetal Toxicity
HICON® is contraindicated in pregnancy because sodium iodide I 131 crosses the placenta and fetal exposure can lead to neonatal hypothyroidism. Multiple reports in the published literature describe hypothyroidism in the neonates following in utero exposure to sodium iodide I 131. Some cases of neonatal hypothyroidism were severe and irreversible. Verify pregnancy status of females of reproductive potential prior to initiating HICON® treatment. Advise females and males of reproductive potential to use effective contraception during treatment with HICON® and for at least six months after the last dose [see Use in Specific Populations (8.1, 8.3)].

5.5 Increased Radiation Exposure to Breast Tissue with Lactation
HICON® is contraindicated in lactating women because sodium iodide I 131 concentrates in the breast via the increased expression of the sodium iodide symporter in breast tissue with lactation. The literature describes moderate to marked radioiodine uptake in the breast tissue for 5-32 weeks post cessation of breast feeding. Advise lactating women to discontinue breast feeding at least 6 weeks prior to administration of sodium iodide I 131 to allow sufficient time for involution to occur and to avoid excess concentration of sodium iodide I 131 in breast tissue. Consider administration of drugs to suppress lactation. Consider diagnostic scintigraphy before administration of sodium iodide I 131 to assess the persistence of uptake by breast tissue. If sodium iodide I 131 is administered in the postpartum period, the lactating mother should not breastfeed the infant [see Use in Specific Populations (8.2)].

5.6 Transient Infertility
Transient dose-related impairment of testicular function in men and transient ovarian insufficiency in women has been reported after sodium iodide I 131 therapy. Consider sperm banking for men who are anticipated to receive cumulative sodium iodide I 131 doses greater than 19,000 MBq (520 mCi) [see Use in Specific Populations (8.3)].

5.7 Risk of Radiation Exposure
Household Contacts
Instruct patients to follow radiation safety precautions after receiving HICON® to minimize the radiation contamination of other persons or the environment. Patients should avoid close contact with others, especially pregnant women and children, and take care to avoid contamination of other persons or the environment with body fluids.

Patients and Healthcare Providers
HICON® contributes to a patient’s overall long-term cumulative radiation exposure, which is
associated with an increased risk of cancer. Follow safe handling and administration to minimize radiation exposure to the patient and healthcare providers.

5.8 Risk of Decreased Effectiveness of Therapy

Certain food or drugs may alter the thyroid uptake of sodium iodide I 131 and diminish its effectiveness. Recent intake of stable iodide in any form, or the use of thyroid or anti-thyroid drugs may diminish thyroid uptake of sodium iodide I 131 [see Drug Interactions (7)].

6 ADVERSE REACTIONS

The following serious adverse reactions are described below and elsewhere in labeling:

- Radiation-induced Thyroiditis [see Warnings and Precautions (5.1)].
- Radiation-induced Toxicities [see Warnings and Precautions (5.2)].
- Hypersensitivity Reactions [see Warnings and Precautions (5.3)].
- Fetal Toxicity [see Warnings and Precautions (5.4), Use in Specific Population (8.1)].
- Increased Radiation Exposure to Breast Tissue with Lactation [see Warnings and Precautions (5.5), Use in Specific Populations (8.2)].
- Transient Infertility [see Warnings and Precautions (5.6), Use in Specific Population (8.3)].
- Radiation Exposure [see Warnings and Precautions (5.7)].

The following adverse reactions have been identified during post-approval use of sodium iodide I 131. Because these reactions are voluntarily reported by from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

- Gastrointestinal disorders: sialadenitis, salivary gland dysfunction, nausea, vomiting, gastritis.
- Cardiac disorders: chest pain, tachycardia.
- Skin and subcutaneous tissue disorders: itching, rash, hives.
- Endocrine disorders: hypothyroidism, hyperthyroidism, thyrotoxic crisis, hypoparathyroidism.
- General disorders and administration site conditions: local swelling of thyroid or sites of iodide avid tumor.
- Hematologic and lymphatic disorders including fatalities: bone marrow depression, anemia, leukopenia, thrombocytopenia, and blood dyscrasia.
- Neoplasms benign, malignant and unspecified (including cysts and polyps): acute leukemia, solid cancer.
- Eye disorders: lacrimal gland dysfunction.
- Congenital, familial and genetic disorders: congenital hypothyroidism, chromosomal abnormalities.
- Immune system disorders: bronchospasm.
- Nervous system disorders: headache, cerebral edema.
- Respiratory, thoracic and mediastinal disorders: radiation pneumonitis, pulmonary fibrosis.

* In patients with iodide-avid brain metastases
** In patients with iodide-avid lung metastases

7 DRUG INTERACTIONS

- Concomitant use of bone marrow depressants may enhance the depression of the hematopoietic system caused by the use of large doses of sodium iodide I 131 [see Warnings and Precautions (5.2)].
- Many drugs and iodide-containing foods interfere with the accumulation of radioiodide by the thyroid. Review the patients history, current medications, and recent diagnostic tests prior to the administration of sodium iodide I 131 [see Warnings and Precautions (5.8)].
- Advise patients to maintain a low-iodide diet two weeks prior to radioiodide administration and continue for several days during the uptake or imaging process and to discontinue taking the
following products before they undergo the procedure as shown in Table 3.

<table>
<thead>
<tr>
<th>Type of Medication</th>
<th>Recommended time of withdrawal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thionamide medications (e.g., propylthiouracil, methimazole, carbimazole)</td>
<td>3 days</td>
</tr>
<tr>
<td>Multivitamins containing iodide</td>
<td>10 days</td>
</tr>
<tr>
<td>Natural or synthetic thyroid hormones</td>
<td></td>
</tr>
<tr>
<td>triiodothyronine</td>
<td>2 weeks</td>
</tr>
<tr>
<td>thyroxine</td>
<td>4 weeks</td>
</tr>
<tr>
<td>Iodide-containing foods: iodized salt, dairy products, egg yolks, seafood, turkey and liver</td>
<td>2 weeks</td>
</tr>
<tr>
<td>Kelp, agar, carrageenan, Lugol solution</td>
<td>3 weeks</td>
</tr>
<tr>
<td>Saturated solution of potassium iodide</td>
<td>3 weeks</td>
</tr>
<tr>
<td>Topical iodide (e.g., surgical skin preparation)</td>
<td>3 weeks</td>
</tr>
<tr>
<td>Intravenous radiographic contrast agents</td>
<td></td>
</tr>
<tr>
<td>Water soluble</td>
<td>2 months</td>
</tr>
<tr>
<td>Lipophilic</td>
<td>6 months</td>
</tr>
<tr>
<td>Amiodarone</td>
<td>6 months</td>
</tr>
</tbody>
</table>

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary
HICON® is contraindicated in pregnancy because fetal exposure can lead to neonatal hypothyroidism, which in some cases is severe and irreversible. Data from the published literature describe thyroid abnormalities after fetal exposure; including agenesis of the thyroid and hypothyroidism (see Data). No animal reproductive studies have been conducted.

Clinical Considerations,
Fetal/Neonatal Adverse Reactions
A fetus exposed to sodium iodide I 131 can develop neonatal hypothyroidism. Delay in diagnosis of neonatal hypothyroidism after exposure to sodium iodide I 131 in utero can result in severe sequelae such as decreased mental capacity and delayed bone age. Monitor thyroid function in any infant born after in utero exposure to sodium iodide I 131.

Data
Human Data
Sodium iodide I 131 crosses the placenta and the fetal thyroid begins to concentrate iodide during the 10-12th week of gestation. In literature reports of maternal exposures to sodium iodide I 131 at doses of 333 – 8325 MBq (9 – 225 mCi) during 4-26 weeks gestational age, the most common adverse outcomes were hypothyroid infants and children.

8.2 Lactation

Risk Summary
HICON® is contraindicated during lactation because I 131 concentrates in the breast during lactation via the increased expression of the sodium iodide symporter in breast tissue [see Warnings and Precautions (5.5)]. If sodium iodide I 131 is administered in the postpartum period, the lactating mother should not
breastfeeding. In addition, to minimize the absorbed radiation dose to the breast tissue, breastfeeding and breast-pumping should be discontinued for at least 6 weeks before administration of sodium iodide I 131 (see Data). Women may breastfeed with the birth of another child.

Infants exposed to sodium iodide I 131 through breast milk are at risk for development of hypothyroidism because sodium iodide I 131 is distributed into breast milk and may reach concentrations equal to or greater than concentrations in maternal plasma (see Data).

Data

Human Data

Limited published literature describes sodium iodide I 131 transfer into breast milk and thyroidal uptake by the breastfed infant. The amount of sodium Iodide I 131 detected in the breast milk at 36-48 hours after administration is 1-27% of the injected dose (with injected doses between 1.1 – 5143 MBq).

8.3 Female and Males of Reproductive Potential

HICON® is contraindicated in pregnancy because of the risk of fetal hypothyroidism [see Use in Specific Populations (8.1)].

Pregnancy Testing

Obtain a pregnancy test in females of reproductive potential and verify the absence of pregnancy before initiating treatment [see Dosage and Administration (2.2), Warnings and Precautions (5.4)].

Contraception

Advise females and males of reproductive potential to use effective contraception during treatment with HICON® and for at least six months after the last dose of HICON®.

Infertility

Females

Fertility may be impaired with HICON® treatment. Transient amenorrhea and ovarian insufficiency have been observed after sodium iodide I 131 therapy in females. The literature describes reports of transient menstrual cycle irregularities, including amenorrhea, and ovarian failure in females treated with cumulative doses of 1000 – 59,000 MBq (27 – 1594 mCi) sodium iodide I 131.

Males

Fertility may be impaired with HICON® treatment. Discuss sperm banking for males who are expected to receive a high cumulative dose of sodium iodide I 131. Transient dose-related impairment of testicular function after sodium iodide I 131 therapy has been reported in the published literature. The literature describes reports of males treated with sodium iodide I 131 at doses of 370 MBq – 22,000 MBq (10 – 595 mCi) resulting in transiently impaired testicular function (including spermatogenesis). Permanent impairment is described with high cumulative doses ranging from 19,000 – 29,000 MBq (520 – 800 mCi).

8.4 Pediatric Use

Safety and efficacy in pediatric patients have not been established. Pediatric patients are at an increased lifetime risk for malignancy from radiation exposure

8.5 Geriatric Use

Clinical experience has not identified differences in safety or effectiveness in geriatric patients compared to younger patients. However, elderly patients are more likely to have decreased renal function and radiation exposure is greater in patients with impaired renal function [see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)].

8.6 Renal Impairment

HICON® is primarily excreted by the kidneys. Renal function impairment decreases excretion of sodium iodide I 131 and increases the radiation exposure and risk of radiation toxicity. For patients with
a history of renal impairment, evaluate renal function for therapeutic planning and consider dosimetry. Sodium Iodide I 131 is dialyzable. Hemodialysis can be used to reduce total body radiation exposure [see Clinical Pharmacology (12.3)].

10 OVERDOSAGE
In case of exposure to a radioactive dose of sodium iodide I 131 exceeding the intended therapeutic dose, provide general supportive care, promote frequent voiding, monitor for bone marrow and thyroid suppression. Consider administering a thyroid blocking agent (e.g. potassium iodide (KI) or perchlorate) promptly within 4 to 6 hours after the exposure. Assess the benefit of administering a thyroid blocking agent against the risk of failure of sodium iodide I 131 therapy. Appropriate replacement therapy is recommended if hypothyroidism occurs.

11 DESCRIPTION
HICON®, a radioactive therapeutic agent, provides a concentrated solution of sodium iodide I 131 with a radioconcentration of 37,000 MBq/mL (1,000 mCi/mL). Each mL of the concentrated solution contains 37,000 MBq of no-carrier-added sodium iodide I 131, disodium edetate dihydrate USP as a stabilizer, sodium thiosulfate pentahydrate USP as a reducing agent, and dibasic sodium phosphate anhydrous USP. The pH of the concentrated solution is between 7.5 and 10.

The concentrated solution provided with HICON® is used for the preparation of sodium iodide I 131 capsules or sodium iodide I 131 solution of varying strengths for oral administration for therapy.

Sodium iodide I 131 solution is designated chemically as Na 131I and has a molecular weight of 153.99. Hard gelatin capsules, provided for the preparation of the sodium iodide I 131 capsules final dosage form, contain approximately 300 mg of dibasic sodium phosphate anhydrous USP as the absorbing buffer.

11.1 Physical Characteristics
Iodine I-131 decays by beta emission and associated gamma emission with a physical half-life of 8.04 days. The principal radiation emissions are listed in Table 4.

Table 4 Principal Radiation Emission Data from Decay of Sodium Iodide I 131

<table>
<thead>
<tr>
<th>Radiation</th>
<th>Mean % per Disintegration</th>
<th>Mean Energy (keV)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beta-1</td>
<td>2.1%</td>
<td>69.4</td>
</tr>
<tr>
<td>Beta-3</td>
<td>7.2%</td>
<td>96.6</td>
</tr>
<tr>
<td>Beta-4</td>
<td>89.4%</td>
<td>191.6</td>
</tr>
<tr>
<td>Gamma-7</td>
<td>6.1%</td>
<td>284.3</td>
</tr>
<tr>
<td>Gamma-14</td>
<td>81.2%</td>
<td>364.5</td>
</tr>
<tr>
<td>Gamma-18</td>
<td>7.1%</td>
<td>637.0</td>
</tr>
</tbody>
</table>

11.2 External Radiation
The specific gamma-ray constant for iodide I 131 is 4.26 × 10⁻¹³ C·m²·kg⁻¹·MBq⁻¹·s⁻¹ (2.2 R·cm²/mCi·hr). The first half-value thickness of lead (Pb) for iodide I 131 is 0.27 cm. A range of values for the relative attenuation of the radiation emitted by iodide I 131 that results from interposition of various thicknesses of Pb is shown in Table 5. For example, the use of 2.59 cm of Pb will decrease the external radiation exposure by a factor of about 1,000.
To correct for physical decay of iodine I 131, the fractions that remain at selected intervals after the time of calibration are shown in Table 6.

**Table 6 Physical Decay Chart: Iodine I-131 Half-Life 8.04 days**

<table>
<thead>
<tr>
<th>Days</th>
<th>Fraction Remaining</th>
<th>Days</th>
<th>Fraction Remaining</th>
<th>Days</th>
<th>Fraction Remaining</th>
</tr>
</thead>
<tbody>
<tr>
<td>0*</td>
<td>1.000</td>
<td>11</td>
<td>.388</td>
<td>22</td>
<td>.151</td>
</tr>
<tr>
<td>1</td>
<td>.918</td>
<td>12</td>
<td>.356</td>
<td>23</td>
<td>.138</td>
</tr>
<tr>
<td>2</td>
<td>.842</td>
<td>13</td>
<td>.327</td>
<td>24</td>
<td>.127</td>
</tr>
<tr>
<td>3</td>
<td>.773</td>
<td>14</td>
<td>.300</td>
<td>25</td>
<td>.116</td>
</tr>
<tr>
<td>4</td>
<td>.709</td>
<td>15</td>
<td>.275</td>
<td>26</td>
<td>.107</td>
</tr>
<tr>
<td>5</td>
<td>.651</td>
<td>16</td>
<td>.253</td>
<td>27</td>
<td>.098</td>
</tr>
<tr>
<td>6</td>
<td>.597</td>
<td>17</td>
<td>.232</td>
<td>28</td>
<td>.090</td>
</tr>
<tr>
<td>7</td>
<td>.548</td>
<td>18</td>
<td>.213</td>
<td>29</td>
<td>.083</td>
</tr>
<tr>
<td>8</td>
<td>.503</td>
<td>19</td>
<td>.195</td>
<td>30</td>
<td>.076</td>
</tr>
<tr>
<td>9</td>
<td>.461</td>
<td>20</td>
<td>.179</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>.423</td>
<td>21</td>
<td>.164</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Calibration time

**12 CLINICAL PHARMACOLOGY**

**12.1 Mechanism of Action**

Iodide is actively transported by the sodium-iodide symporter (NIS) protein, in thyroid follicular cells. Iodide is concentrated in follicular cells to levels up to 50 times higher than in the plasma. Iodide is metabolically oxidized by thyroid peroxidase to iodinium (I⁺⁺) which in turn iodinates tyrosine residues of thyroglobulin (tri or tetra-iodinated tyrosine). The beta emission of I 131 is responsible for the therapeutic effect.

**12.2 Pharmacodynamics**

The relationship between the extent of iodide I 131 exposure and pharmacologic effects has not been explored in clinical trials.

**12.3 Pharmacokinetics**

**Absorption**

Following oral administration of HICON®, 90% of the administered radioactivity of Iodide I 131 is systemically absorbed in the first 60 minutes.
**Distribution**
Following absorption, I 131 is distributed within the extra-cellular space. It is actively transported by the sodium-iodide symporter (NIS) protein, and binds to thyroglobulin resulting in accumulation in the thyroid. The thyroid uptake of iodide is usually increased in hyperthyroidism and in goiter, and is decreased in hypothyroidism. Sodium Iodide I 131 also accumulates in the stomach, choroid plexus, salivary glands, breast, liver, gall bladder, and kidneys.

**Elimination**

**Metabolism**
In thyroidal follicular cells iodide is oxidized through the action of thyroid peroxidase to iodinium (I⁺) which in turn iodinates tyrosine residues of thyroglobulin.

**Excretion**
Sodium iodide I 131 is excreted in urine and feces. The normal range of urinary excretion is 37% to 75% of the administered dose, varying with the thyroid and renal function of the patient. Fecal excretion is about 10%.

### 16 HOW SUPPLIED/STORAGE AND HANDLING

#### 16.1 How Supplied
HICON® is supplied in 1 mL clear vials that contain approximately 37,000 MBq (250 mCi), 18,500 MBq (500 mCi), and 37,000 MBq (1,000 mCi) at the time of calibration.

<table>
<thead>
<tr>
<th>NDC</th>
<th>Volume of Concentrated Solution</th>
<th>Total Radioactivity per Vial</th>
</tr>
</thead>
<tbody>
<tr>
<td>65174-880-25</td>
<td>0.25 mL</td>
<td>9,250 &lt;MBq (250 mCi)</td>
</tr>
<tr>
<td>65174-880-50</td>
<td>0.50 mL</td>
<td>18,500 MBq (500 mCi)</td>
</tr>
<tr>
<td>65174-880-00</td>
<td>1 mL</td>
<td>37,000 MBq (1,000 mCi)</td>
</tr>
</tbody>
</table>

A minimum of one blister package of 10 empty large hard gelatin capsules and a minimum of one blister package of 10 small hard gelatin capsules containing approximately 300 mg of dibasic sodium phosphate anhydrous as the absorbing buffer are supplied along with HICON® for the preparation of sodium iodide I 131 capsules, therapeutic.

#### 16.2 Storage
HICON® should be stored between 2°C and 25°C (36°F and 77°F). Store and dispose of HICON® in compliance with the appropriate regulations of the government agency authorized to license the use of this radionuclide.

Discard unused capsules after all HICON® solution has been dispensed or expired. New blister packages of hard gelatin capsules are provided with each new shipment of HICON®.

This radiopharmaceutical is approved for use by persons under license by the Nuclear Regulatory Commission or the relevant regulatory authority of an Agreement State.

### 17 PATIENT COUNSELING INFORMATION

Radiation Safety Precautions [see Warnings and Precautions (5.7)].
Review the most recent professional society guidelines and publications that describe important components of the patient counseling process and discuss measures to minimize inadvertent radiation exposure to the patient.

**Fetal Toxicity** [see Contraindications (4), Warnings and Precautions (5.4) and Use in Specific Populations (8.1, 8.3)].
- Advise female patients of the risk to a fetus.
- Advise females and males of reproductive potential to use effective contraception during treatment with HICON® and for at least 6 months after the last dose.
- Advise female patients to contact their healthcare provider with a known or suspected pregnancy.

**Lactation**
- Instruct women to stop breastfeeding and breast-pumping at least 6 weeks prior to HICON® administration [see Contraindications (4), Warnings and Precautions (5.5) and Use in Specific Populations (8.2)].

**Effects on Fertility**
- Advise females and males of reproductive potential of the potential for impaired fertility with HICON® treatment [see Warnings and Precautions (5.6) and Use in Specific Populations (8.3)].

Manufactured by:
Jubilant DraxImage Inc., Kirkland, Québec Canada, H9H 4J4
Art rev.: 1.0

**PRINCIPAL DISPLAY PANEL**

![HICON® SODIUM IODIDE I 131 SOLUTION, USP](image)
Total Radioactivity: 250 mCi
Volume: 0.25 mL
Radioactive Concentration: 1000 mCi/mL
Calibration Date: 
Specific Activity: No carrier added.
Expiry Date: 
LOT:
Each mL of the aqueous solution contains Sodium Iodide I-131 Solution as above, < 2 mg of Disodium Edetate Dihydrate USP, < 22 mg of Sodium Thiosulfate Pentahydrate USP, and < 40 mg of Dibasic Sodium Phosphate Anhydrous USP.
The pH of the solution is between 7.5 and 10.0.

CAUTION RADIOACTIVE MATERIAL

502880

HICON® SODIUM IODIDE I 131 SOLUTION, USP

Therapeutic Oral

Uses: Compounding of therapeutic oral solutions or capsules
Storage: 2 °C to 25 °C
Rx only

Manufactured by:
Jubilant DraxImage Inc.
Kirkland Québec H9H 4J4 Canada

510808

510809

500 mCi

HICON® SODIUM IODIDE I 131 SOLUTION, USP

RADIOACTIVE CONCENTRATION: 1000 mCi/mL

THERAPEUTIC ORAL

Lot: Exp: 
Rx only

Jubilant DraxImage Inc.
Total Radioactivity: 500 mCi
Volume: 0.50 mL
Radioactive Concentration: 1000 mCi/mL
Calibration Date:
Specific Activity: No carrier added.
Expiry Date:

LOT:
Each mL of the aqueous solution contains Sodium Iodide I-131 Solution as above, < 2 mg of Disodium Edetate Dihydrate USP, < 22 mg of Sodium Thiosulfate Pentahydrate USP, and < 40 mg of Dibasic Sodium Phosphate Anhydrous USP. The pH of the solution is between 7.5 and 10.0.

CAUTION
RADIOACTIVE MATERIAL

502880
HICON®
SODIUM IODIDE I 131 SOLUTION, USP

Therapeutic Oral

Uses: Compounding of therapeutic oral solutions or capsules
Storage: 2 °C to 25 °C
Rx only

Manufactured by:
Jubilant DraxImage Inc.
Kirkland Québec H9H 4J4 Canada

510810

1000 mCi

HICON®
SODIUM IODIDE I 131 SOLUTION, USP

RADIOACTIVE CONCENTRATION: 1000 mCi/mL

THERAPEUTIC ORAL

Lot: Exp:

Rx only
Jubilant DraxImage Inc.
HICON
sodium iodide i 131 solution

Product Information

<table>
<thead>
<tr>
<th>Product Type</th>
<th>Item Code (Source)</th>
<th>NDC:65174-880</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUMAN PRESCRIPTION DRUG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Route of Administration</td>
<td>ORAL</td>
<td></td>
</tr>
</tbody>
</table>

Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>SODIUM IODIDE I-131</td>
<td>IODIDE ION I-131</td>
<td>1 mCi in 1 mL</td>
</tr>
</tbody>
</table>

Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edetate Disodium (UNII: 7FLD91C86K)</td>
<td></td>
</tr>
<tr>
<td>Sodium Thiosulfate (UNII: HX1032V43M)</td>
<td></td>
</tr>
<tr>
<td>SODIUM PHOSPHATE, DIBASIC, ANHYDROUS (UNII: 22ADO53M6F)</td>
<td></td>
</tr>
</tbody>
</table>

Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:65174-880-25</td>
<td>1 in 1 KIT</td>
<td>04/07/2003</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>NDC:65174-880-50</td>
<td>1 in 1 KIT</td>
<td>04/07/2003</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>NDC:65174-880-00</td>
<td>1 in 1 KIT</td>
<td>04/07/2003</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>NDC:65174-880-25</td>
<td>.25 mL in 1 VIAL; Type 0: Not a Combination Product</td>
<td>04/07/2003</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>NDC:65174-880-50</td>
<td>.5 mL in 1 VIAL; Type 0: Not a Combination Product</td>
<td>04/07/2003</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>NDC:65174-880-00</td>
<td>1 mL in 1 VIAL; Type 0: Not a Combination Product</td>
<td>04/07/2003</td>
<td></td>
</tr>
</tbody>
</table>
**Marketing Information**

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA</td>
<td>NDA021305</td>
<td>04/07/2003</td>
<td></td>
</tr>
</tbody>
</table>

**Labeler** - Jubilant DraxImage Inc. (243604761)

**Registrant** - Jubilant DraxImage Inc. (243604761)

**Establishment**

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jubilant DraxImage Inc.</td>
<td></td>
<td>243604761</td>
<td>MANUFACTURE(65174-880)</td>
</tr>
</tbody>
</table>

Revised: 9/2016

Jubilant DraxImage Inc.